(Q38587958)

4 September 2017

title

Emerging therapeutic approaches in renal cell carcinoma (English)

1 reference

4 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26376584%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Brian I Rini

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26376584%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

17 September 2015

1 reference

Expert Review of Anticancer Therapy

4 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26376584%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26376584%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26376584%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

1305-1314

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26376584%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

A phase I study of sunitinib plus bevacizumab in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Cabozantinib as a novel therapy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1090315

10.1586/14737140.2015.1090315

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26376584%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference